榄香烯联合洛铂治疗晚期肺癌合并恶性胸腔积液的临床疗效

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1031 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical efficacy of elemene combined with lobaplatin in the treatment of advanced lung cancer patients with malignant pleural effusion (MPE).Methods The subjects of study were 60 cases of advanced lung cancer patients with MPE who were admitted to the Department of Respiratory Medicine or Thoracic Surgery, Hebei General Hospital from July 2019 to July 2022. The enrolled patients were randomly divided into the control group and the treatment group, with 30 cases in each group. Patients in the control group were given lobaplatin, and those in the treatment group were treated with elemene on this basis. Both groups were treated for 4 weeks. Further comparison was performed on the clinical efficacy, adverse reaction, Karnofsky Performance Scale (KPS) scores in the two groups. Meanwhile, T lymphocyte subsets (CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺), serum tumor markers [carcinoembryonic antigen(CEA) and squamous cell carcinoma antigen(SCC) and Cytokeratin 19 Fragment (CYFRA21-1)] levels were detected and compared before and after treatment.Results After 4 weeks of treatment, the symptom remission rate of the treatment group was significantly improved compared with the control group (83.3% vs. 56.7%), and the incidence of adverse reactions was reduced than that of the control group (30.0% vs. 63.3%; P<0.05). after treatment, both groups were significantly improved compared with before treatment, but the scores of KPS, and the levels of CD3⁺ and CD4⁺, and the ratio of CD4⁺/CD8⁺ in the treatment group increased than those in the control group (73.33±10.61 vs. 68.33±8.34;66.50±3.46 vs. 64.07±2.99;55.10±17.69 vs. 36.18±7.45;3.03±0.08 vs. 2.65±0.46; P<0.05), and CD8⁺ level in the treatment group was significantly lower (P<0.05). In addition, after treatment, the level of CD8⁺, and the levels of serum CEA, SCC and CYFRA21-1 in the treatment group were significantly lower than those in the control group (P<0.05).Conclusions Elemene combined with lobaplatin has significant clinical effect in the treatment of advanced lung cancer patients with MPE, which can reduce the adverse reactions of lobaplatin, and may be related with the improvement of the cellular immune level and decrease of the content of tumor biomarkers of patients.

Key words： elemene lobaplatin lung cancer malignant pleural effusion immune function serum tumor markers

Received: 10 September 2022

ZTFLH:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Shuhui
	GAO Haixiang
	YAN Li
	XU Jinwei
	ZHANG Guibin

Cite this article:

GAO Shuhui,GAO Haixiang,YAN Li等. Clinical efficancy of elemene combined with lobaplatin in treatment of advanced lung cancer patients with malignant pleural effusion[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(5): 398-401.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I5/398

[1]	赵媛媛, 周建英, 范云, 等. BRAF V600突变型非小细胞肺癌的治疗进展[J]. 中国癌症杂志, 2021, 31(12):1145-1152.
[2]	胥瑞婷, 马音, 朱炜炜. 中医药联合靶向药物治疗非小细胞肺癌的研究进展[J]. 现代中西医结合杂志, 2020, 29(12):1359-1363.
[3]	中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会.Ⅳ期原发性肺癌中国治疗指南(2021年版)[J].中华肿瘤杂志, 2021, 43(1):39-59.
[4]	姜敏, 迟峰, 吴荣.贝伐单抗联合卡铂治疗非小细胞肺癌恶性胸腔积液的临床研究[J].临床肺科杂志, 2017, 22(5):813-816.
[5]	温少迪, 沈波.非小细胞肺癌免疫治疗作用机制及临床研究现状[J].南京医科大学学报(自然科学版), 2020, 40(11):1739-1746.
[6]	闵诗惠,郑强强,张白露, 等.洛铂与顺铂胸腔灌注化疗治疗恶性胸腔积液的疗效及不良反应的Meta分析[J].中国肺癌杂志, 2019, 22(2):90-98.
[7]	史亚博, 陈婷婷.榄香烯抗肿瘤药效及临床应用研究进展[J].中医临床研究, 2020, 12(18):40-45.
[8]	周仲瑛.中医内科学[M].7版.北京:中国中医药出版社, 2003:408-420.
[9]	金志超, 施展, 花宝金.中医药防治恶性胸腔积液的研究评述[J].中华中医药杂志, 2017, 32 (8):3339-3341.
[10]	邹媚, 李燕, 周自华,等. 香菇多糖联合白介素-2序贯洛铂胸腔灌注治疗非小细胞肺癌合并恶性胸腔积液的疗效观察[J]. 中国处方药, 2021, 19(9):121-123.
[11]	武淑芳, 张美峰, 宁新宇. 胸腔镜下肺叶切除术患者围术期多模式镇痛效果及其对免疫功能的影响[J]. 武警医学, 2021, 32(6):468-471,475.
[12]	杨柳, 李新, 宣奇迹, 等.小细胞肺癌血清相关肿瘤标志物研究进展[J].临床军医杂志, 2020, 48(9):1113-1115.
[13]	易媛, 龙冠晗, 唐湘宇.肺癌与肿瘤标志物的研究进展[J].当代医学, 2022, 28(16):190-194.
[14]	李天林, 余薇, 陈亮, 等. 肺部穿刺活检联合血清SCC,CEA,NSE诊断肺癌的价值[J]. 福建医药杂志,2021,43(3):26-29.
[15]	张利祥, 潘静, 赵洁,等. 痰液基细胞学检查与血清CYFRA21-1,CEA,NSE联合检测对肺癌的诊断价值[J]. 现代检验医学杂志, 2019, 34(3):99-103.
[16]	邓伟伟, 黄艳春.血清CYFRA21-1和CEA对非小细胞肺癌预后评价价值的Meta分析[J].中华临床医师杂志(电子版), 2014, 8(12):2330-2334.
[17]	宋春青, 张颖, 张志国, 等.β-榄香烯联合吉非替尼治疗一线应用吉非替尼后缓慢进展晚期肺腺癌患者的临床疗效[J].国际肿瘤学杂志, 2020, 47(5):272-277.
[18]	袁琴, 王虚实, 王君钰, 等.榄香烯乳注射液对原发性肝癌患者免疫功能的影响[J].癌症进展, 2016, 14(7):664-666,670.
[19]	梁雨辰. β-榄香烯对放疗肺癌细胞培养基诱导的HUVEC细胞作用研究[D].大连:大连医科大学, 2019.
[20]	曾晖, 张永军, 张爱琴, 等.榄香烯逆转肺癌化疗药物耐药的实验研究[J].新中医, 2016, 48(6):271-273.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(3): 243-244.